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High-dose intravenous immunoglobulin is a widely used therapeutic preparation of highly purified immunoglobulin G (IgG) antibodies. It is administered at high doses (1-2 grams per kilogram) for the suppression of autoantibody-triggered inflammation in a variety of clinical settings 1 . This anti-inflammatory activity of intravenous immunoglobulin is triggered by a minor population of IgG crystallizable fragments (Fcs), with glycans terminating in a2,6 sialic acids (sFc) that target myeloid regulatory cells expressing the lectin dendritic-cell-specific ICAM-3 grabbing non-integrin (DC-SIGN; also known as CD209) [2] [3] [4] . Here, to characterize this response in detail, we generated humanized DC-SIGN mice (hDC-SIGN), and demonstrate that the anti-inflammatory activity of intravenous immunoglobulin can be recapitulated by the transfer of bonemarrow-derived sFc-treated hDC-SIGN 1 macrophages or dendritic cells into naive recipients. Furthermore, sFc administration results in the production of IL-33, which, in turn, induces expansion of IL-4-producing basophils that promote increased expression of the inhibitory Fc receptor FccRIIB on effector macrophages. Systemic administration of the T H 2 cytokines IL-33 or IL-4 upregulates FccRIIB on macrophages, and suppresses serum-induced arthritis. Consistent with these results, transfer of IL-33-treated basophils suppressed induced arthritic inflammation. This novel DC-SIGN-T H 2 pathway initiated by an endogenous ligand, sFc, provides an intrinsic mechanism for maintaining immune homeostasis that could be manipulated to provide therapeutic benefit in autoimmune diseases.
Binding of intravenous immunoglobulin (IVIG) or sFc to specific ICAM-3 grabbing non-integrin-related 1 (SIGN-R1) on splenic marginal zone macrophages suppresses autoantibody-mediated inflammation 4 . Although the human orthologue of SIGN-R1, DC-SIGN, showed similar binding specificity for sFc as mouse SIGN-R1, its expression pattern is broader, as it is detected systemically on myeloid-derived cells, including dendritic cells, macrophages and some monocytes 5, 6 . DC-SIGN recognizes high-mannose glycans from a variety of pathogens, and acts as a pattern recognition receptor bridging innate and adaptive immunity 7 . Ligation of DC-SIGN by bacteria-derived mannosylated glycans can induce their internalization, and also synergize with other innate receptor pathways promoting inflammation and resistance to infection. In contrast, binding of sFc to DC-SIGN requires both carbohydrate and protein determinants, and results in an anti-inflammatory response 2, 4 . The immunosuppressive potential of DC-SIGN has been documented following ligation by HIV-derived gp120 or anti-DC-SIGN antibody, which promotes the development of tolerogenic, IL-10-producing dendritic cells, and interferes with Toll-like receptor (TLR) signalling 8, 9 . To study human DC-SIGN in the context of IVIG anti-inflammatory activity, we expressed hDC-SIGN-driven by its endogenous promoter to reproduce the characteristically broad in vivo expression pattern of hDC-SIGN-in a mouse. Human bacterial artificial chromosome (BAC) clones encoding the DC-SIGN gene and its regulatory regions were introduced as a transgene into mice (Fig. 1a) . Transgenic mice showed surface expression of this human lectin on dendritic cells, macrophages, and monocytes, in the peripheral blood, bone marrow and spleen, resembling the human expression pattern of DC-SIGN ( Supplementary Fig. 2a-c) , although a higher percentage of murine monocytes were found to express DC-SIGN.
To determine if hDC-SIGN could substitute for SIGN-R1 in mediating IVIG protection, hDC-SIGN 1 mice were crossed to SIGN-R1-deficient animals (hDC-SIGN
) and challenged with arthritogenic K/BxN serum 10 . Both induction of arthritis and responsiveness to IVIG and sFc were similar in wild-type mice and hDC-SIGN
2/2 mice ( Fig. 1b and Supplementary Fig. 3a ). In contrast, induced arthritis was not suppressed by IVIG or sFc in (white bars), or hDC-SIGN 1 /SIGN-R1 2/2 (grey bars) mice were administered K/BxN sera and sFc. **P , 0.001 determined by a Fisher least significant difference (LSD) post-hoc test. c, AsialoFc-(black bars) or sFc-(white bars) treated wild-type and hDC-SIGN 1 bone-marrow derived macrophages (BMMW) were administered to K/BxN-sera-treated wild-type recipients. *P , 0.05 determined by Tukey's post-hoc test. d, PBS (black bars) or sFctreated hDC-SIGN 1 bone-marrow-derived macrophages (white bars) were administered to SIGN-R1 2/2 and FccRIIB 2/2 recipients. Means and standard deviations are plotted; **P , 0.001 determined by Tukey's post-hoc test.
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2/2 mice. Thus, hDC-SIGN expression was sufficient to trigger the IVIG and sFc anti-inflammatory response.
A related lectin, DC-SIGN-R, is linked to DC-SIGN on the BAC transgene (Fig. 1a) . hDC-SIGN-R has reduced affinity to sFc as compared to hDC-SIGN ( Supplementary Fig. 3b ). To define the contribution of DC-SIGN-R to sFc anti-inflammatory activity, mice that express hDC-SIGN alone as a transgene 11 were crossed with SIGN-
). These mice were protected from inflammatory arthritis by IVIG ( Supplementary Fig. 3c ). Further, selective blockade of hDC-SIGN in transgenic hDC-SIGN
2/2 mice expressing both hDC-SIGN and hDC-SIGN-R resulted in a loss of IVIG protection in vivo ( Supplementary Fig.  3d ). These results support a requirement for hDC-SIGN but not hDC-SIGN-R in this anti-inflammatory response triggered by sFc.
Next, we sought to determine if stimulation of hDC-SIGN 1 cells matured from bone marrow with sFc was sufficient to induce an antiinflammatory response. Bone-marrow-derived macrophages and dendritic cells cultured from hDC-SIGN 1 transgenic animals expressed hDC-SIGN, but not hDC-SIGN-R or SIGN-R1 ( Supplementary Fig. 4a , b, c). Bone-marrow-derived cells cultured from hDC-SIGN 1 transgenic or wild-type mice were pulsed for 30 min with sFc or asialylated Fcs (asialoFc) at a concentration representative of in vivo treatments. The treated cells were collected, washed and administered to wild-type mice, which were then challenged with K/BxN serum ( Supplementary Fig.  4d ). Mice receiving hDC-SIGN 1 bone-marrow-derived macrophages or dendritic cells pulsed with sFc or IVIG showed reduced joint inflammation as compared to recipient mice that received wild-type cells, or hDC-SIGN 1 cells pulsed with asialoFc ( Fig. 1c and Supplementary Fig.  4e, f. ). The anti-inflammatory response triggered by transferred sFcstimulated hDC-SIGN 1 bone-marrow-derived macrophages required the expression of the inhibitory Fc receptor (FcR) FccRIIB, as FccRIIB 2/2 recipient mice were not protected from inflammation induced by K/BxN serum (Fig. 1d) . Collectively, these results were consistent with the in vivo requirements for IVIG protection previously defined [1] [2] [3] [4] , and demonstrated that ligation of hDC-SIGN by sFc on bone-marrow-derived myeloid cells is sufficient to induce an antiinflammatory cellular response.
DC-SIGN engagement has been reported to result in dendritic cell production of IL-10 (refs 7-8), making this anti-inflammatory cytokine an appealing candidate responsible for mediating IVIG antiinflammatory activity. However, IL-10 2/2 mice were protected from induced arthritis by IVIG similarly to wild-type controls (Supplementary Fig. 5 ). We next addressed other cytokines that could be responsible for this response. The T H 2 cytokine IL-4 has been shown to upregulate FccRIIB surface expression on peripheral monocytes 12 , and increase the threshold for activation by pathogenic immune complexes, consistent with the FccRIIB requirement of IVIG 1, 13, 14 . Therefore, sFc-treated DC-SIGN 1 bone-marrow-derived macrophages were administered to naive wild-type mice or IL-4 2/2 mice, and the recipient mice challenged with K/BxN serum. Wild-type recipients were protected from induced arthritis, whereas IL-4 2/2 recipients were not (Fig. 2a) .
These results led us to predict that IVIG anti-inflammatory activity would require IL-4 signalling. Indeed, mice deficient in IL-4 (IL-4 ; Fig. 2c ), were not protected from K/BxN-induced inflammation by IVIG or sFc. Further, monocytes in the peripheral blood and bone marrow of wild-type mice, but not IL-4Ra 2/2 mice, upregulated FccRIIB after sFc administration (Supplementary Fig. 6 ). Next we examined whether exogenous T H 2 cytokines could also suppress autoantibody-induced inflammation. Mice were treated with cytokine immune complexes (ic) 15 of T H 2 cytokines IL-4 (IL-4ic), and IL-13 (IL-13ic), or a non-T H 2 cytokine complex of IL-3 (IL-3ic), and challenged with K/BxN serum. Inflammation was significantly attenuated after single administration of IL-4ic or IL-13ic, but not after IL-3ic treatment (Fig. 2d) . However, IL-4ic treatment did not attenuate inflammation in FccRIIB 2/2 mice, consistent with IL-4ic also requiring the FccRIIB to suppress inflammation (Fig. 2d) . We next examined whether T H 2 cytokines were induced after IVIG or sFc administration. No changes in Il4 messenger RNA levels were observed ( Fig. 3a and Supplementary Fig. 7a-c) , so we surveyed cytokines known to induce Il4 expression, including IL-33 (refs 16-18) , , and thymic stromal lymphopoietin (TSLP) 18, 21, 22 . Interestingly, Il33 mRNA was upregulated in wild-type mice after IVIG and sFc administration, but remained unchanged SIGN-R1 2/2 mice. We then administered IL-33, IL-25, or TSLP to mice challenged with K/BxN serum. Exogenous IL-33 fully suppressed K/BxN arthritogenic activity and induced IL-4 production in vivo, whereas IL-25 promoted only modest protection, and TSLP provided no protection (Fig. 3b) , all of which correlated with systemic IL-4 and IL-13 levels ( Fig. 3b and Supplementary Fig. 7d, e) . Further, exogenous IL-33 and IL-4ic were unable to ameliorate serum-induced arthritis in IL4Ra 2/2 mice ( Fig. 3c and Supplementary Fig. 7e ), indicating that IL-4Ra acts downstream of IL-33 in this pathway.
Our results support an anti-inflammatory cascade where DC-SIGN ligation by sFc promotes IL-33 production, IL-33 induces IL-4 expression, culminating in FccRIIB upregulation on monocytes and macrophages ( Supplementary Fig. 1 ). To confirm this, hDC-SIGN
2/2 mice were treated with arthritogenic sera and sFc, in combination with a blocking antibody to the IL-33 receptor (anti-IL-33Ra). This intervention ablated the ability of sFc to protect LETTER RESEARCH
2/2 mice ( Fig. 3d and Supplementary Fig. 7f ). Protection of transferred sFc-treated hDC-SIGN 1 bone-marrowderived macrophages was also diminished by anti-IL-33Ra treatment (Fig. 3e) . Further, administration of exogenous IL-4ic or IL-33 increased FccRIIB surface expression on monocytes, whereas IL-25 had no effect ( Fig. 3f and Supplementary Fig. 8 ). IL-4 treatment downregulated FccRIIB expression on B cells (Supplementary Fig. 8 ), consistent with the diverse effects of this cytokine on different leukocyte types. 18 , including basophils 23, 24 , mast cells 25, 26 , eosinophils 27 and progenitor cells 19 . IVIG activity is T-cell independent 4 , thus eliminating these cells as a source of sFc-induced IL-4. To determine whether basophils were involved in this response, we selectively depleted these cells in vivo 28 ( Fig. 4a and Supplementary Figs 9-11 ). Arthritis could be induced in basophil-depleted hDC-SIGN 1 /SIGN-R1 2/2 mice ( Supplementary Fig. 9a ) but the protective capacity of sFc and IVIG was lost (Fig. 4a and Supplementary Fig. 11 ), indicating that these cells have a pivotal role . We next administered sFc and K/BxN sera to IL-4-GFP reporter mice (4get 29 ), and found a twofold increase in GFP
IL-4 can be produced by T cells and several innate immune cell populations
) in the circulation of protected sFctreated mice, indicating that basophils produced IL-4 in response to sFc (Fig. 4b) . To determine whether basophils were ultimately responsible for the anti-inflammatory activity induced by sFc through IL-33, we transferred PBS-or IL-33-treated basophils to K/BxNtreated recipient mice (Fig. 4c, d and Supplementary Fig. 12a-c) . IL-33-treated basophils derived from wild-type or FccRIIB 2/2 mice were equally effective at suppressing arthritic inflammation, reducing serum IL-6 levels, and curbing leukocyte infiltration to arthritic paws (Fig. 4c,  d and Supplementary Fig. 12d, e) . These results confirm the antiinflammatory potential of these cells, and support a model whereby IL-4 produced by basophils increases FccRIIB expression on inflammatory macrophages (Supplementary Fig. 1 ). 
RESEARCH LETTER
Analysing the anti-inflammatory activity of IVIG led to identification of an endogenous, innate pathway in which sialylated IgG, a minor component of serum IgG antibodies, binds DC-SIGN, promoting production of IL-33, which expands IL-4 1 basophils. These cytokines are capable of suppressing autoantibody-mediated inflammation by modulating FccRIIB expression on effector cells (Supplementary Fig. 1 ). IL-4 and IL-33 have pleiotropic activities, and mediate T H 2 responses to helminth parasites and allergens 18 , as well as enhance inflammatory arthritis 30, 31 , in addition to their activities reported here. Cytokine concentration, cellular environment, and differential responses of individual cell types are likely to explain these distinct effector functions.
Various stimuli have been reported to modulate the level of IgG Fc sialylation, and could regulate this intrinsic pathway. Antigenic stimulation results in the production of pro-inflammatory, antigen-specific, asialylated IgG antibodies 2 . Pathogenic autoantibodies, such as those produced during rheumatoid arthritis that recognize citrullinated peptides, similarly show reduced sialic acid as compared to other serum antibodies 32 . Conversely, increases in sialylated IgG antibodies occur during pregnancy 33 , which could contribute to the remission in arthritis seen in pregnant women. Therefore, affecting the sialylation of IgG antibodies could provide an intrinsic mechanism for regulating T H 2 cytokine production by innate myeloid cells in a DC-SIGNdependent manner, provide a means for maintaining homeostasis, and is an attractive therapeutic approach to suppressing inflammation in autoimmune diseases.
METHODS SUMMARY
hDC-SIGN BAC transgenic mice were created using the BAC clone CTD2102F19 (Invitrogen) containing the human DC-SIGN gene. The BAC was linearized by the NotI restriction endonuclease. The human DC-SIGN gene fragment was purified and injected into one-day-old C57BL/6 embryos via pronuclear microinjection. The embryos were then implanted into ICR surrogate females and the resulting progeny were screened by PCR for the presence of the human DC-SIGN transgene. hDC-SIGN 1 mice were crossed to SIGN-R1 2/2 mice to generate hDC-SIGN 
